INCY vs TMDX
Incyte vs TransMedics Group, Inc. — AI-powered side-by-side comparison
VS
TMDX
TransMedics Group, Inc.
60
Buy
| Metric | INCY | TMDX |
|---|
| AI Score |
72
|
60
|
| Price |
$121.08
|
$89.39
|
| P/E Ratio |
14.89×
|
20.22×
|
| ROE |
24.9%
|
40.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
58.7%
|
| Debt / Equity |
0.01×
|
1.68×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.2
|
76.9
|
| Beta |
0.769
|
1.88
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus TMDX.
INCY leads by 12 points.
INCY scores 72/100 (Buy) versus TMDX at 60/100 (Buy).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
TMDX Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 25.8% yoy -- genuine top-line momentum. Risk Analyst remains cautious — bollinger bandwidth of 26.6% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 33.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 25.8% YoY -- genuine top-line momentum — Growth
- EPS growing 105.5% YoY — Growth
Bear Case
- Price-to-book of 8.8x prices in significant intangible value — Value
- RSI at 77 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical